@article{0015c3e4a3e74bae8a8c79d7d22391c9,
title = "Beta-blockers in the treatment of congenital long QT syndrome: Is one beta-blocker superior to another?",
keywords = "arrhythmias, beta-blocker, long QT syndrome, sudden cardiac death",
author = "Wilde, {Arthur A.M.} and Ackerman, {Michael J.}",
note = "Funding Information: Dr. Wilde is a member of the scientific advisory boards of Transgenomics and Sorin. Dr. Ackerman is a consultant for Boston Scientific, Gilead Sciences, Medtronic, and St. Jude Medical. Dr. Ackerman and the Mayo Clinic also receive royalties from Transgenomics for their FAMILION-LQTS and FAMILION-CPVT genetic tests. The authors acknowledge support from the Netherlands CardioVascular Research Initiative (CVON-PREDICT project), the Dutch Heart Foundation , Dutch Federation of University Medical Centres , the Netherlands Organisation for Health Research and Development , and the Royal Netherlands Academy of Sciences . Dr. Ackerman{\textquoteright}s research is supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program . ",
year = "2014",
month = sep,
day = "30",
doi = "10.1016/j.jacc.2014.06.1192",
language = "English (US)",
volume = "64",
pages = "1359--1361",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "13",
}